Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Xennials Therapeutics Australia Pty Ltd
Case Comprehensive Cancer Center
Hospital Sant Joan de Deu
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Peking Union Medical College Hospital
Gustave Roussy, Cancer Campus, Grand Paris